What is HC Wainwright’s Forecast for ETON FY2027 Earnings?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright reduced their FY2027 earnings per share estimates for Eton Pharmaceuticals in a report released on Tuesday, August 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.28 per share for the year, down from their previous forecast of $1.83. HC Wainwright has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is $0.67 per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2028 earnings at $2.23 EPS, FY2029 earnings at $4.25 EPS and FY2030 earnings at $6.53 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The firm had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.

Several other brokerages also recently issued reports on ETON. Canaccord Genuity Group assumed coverage on shares of Eton Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $60.00 price target for the company. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Zacks Research lowered shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Finally, Craig Hallum boosted their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Eton Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $54.50.

Eton Pharmaceuticals Trading Down 1.1%

Shares of Eton Pharmaceuticals stock opened at $41.58 on Thursday. The firm has a market capitalization of $1.14 billion, a PE ratio of -593.92 and a beta of 0.86. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. Eton Pharmaceuticals has a 52-week low of $14.27 and a 52-week high of $50.18. The company’s fifty day moving average price is $38.23 and its two-hundred day moving average price is $28.20.

Insiders Place Their Bets

In related news, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Krempa sold 19,679 shares of Eton Pharmaceuticals stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the completion of the transaction, the insider directly owned 25,249 shares of the company’s stock, valued at $794,586.03. This represents a 43.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently modified their holdings of ETON. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $476,000. Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $623,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $204,000. Quantbot Technologies LP bought a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $165,000. Finally, BlackRock Inc. bought a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $68,629,000. 27.86% of the stock is owned by institutional investors.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright continues to recommend buying ETON and kept its $65 target, indicating that the analyst believes the company’s longer-term growth opportunity remains intact despite the forecast reductions. Eton Pharmaceuticals stock information
• Neutral Sentiment: The analyst expects earnings to ramp over time, forecasting EPS of $1.28 in FY2027, $2.23 in FY2028, $4.25 in FY2029 and $6.53 in FY2030. However, these figures are all below prior estimates, making the growth trajectory less optimistic than previously expected.
• Neutral Sentiment: HC Wainwright’s quarterly projections call for FY2026 EPS of $0.52, followed by quarterly FY2027 EPS estimates of $0.26, $0.30, $0.36 and $0.35. The current-year consensus estimate cited in the reports ranges from $0.67 to $0.75, suggesting that the revised FY2026 forecast is below broader expectations.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to $0.52 from $0.68, FY2027 to $1.28 from $1.83, FY2028 to $2.23 from $3.50, FY2029 to $4.25 from $5.85 and FY2030 to $6.53 from $8.65. The reductions imply slower or less profitable growth and could pressure valuation, particularly with ETON trading well above its 50-day and 200-day moving averages.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from July 27, with a zero-day short-interest ratio. Because the data appears incomplete or anomalous, it provides little meaningful insight into trading sentiment.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.